You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

~ Buy the JANUMET XR (metformin hydrochloride; sitagliptin phosphate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR JANUMET XR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Janumet Xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00532935 ↗ MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) Completed Merck Sharp & Dohme Corp. Phase 3 2008-01-26 A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
NCT00684528 ↗ A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin Unknown status Clalit Health Services Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00684528 ↗ A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin Unknown status Meir Medical Center Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00993187 ↗ Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed Merck Sharp & Dohme Corp. Phase 4 2010-05-04 This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
NCT01065766 ↗ Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182) Completed Merck Sharp & Dohme Corp. 2009-03-01 This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.
NCT01269996 ↗ JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients Completed Chinese University of Hong Kong Phase 4 2011-05-01 To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment regimen of metformin followed by sulfonylurea and intermediate-acting basal insulin in Type 2 Diabetes Mellitus patients.
NCT01336322 ↗ Metformin and Sitagliptin in Women With Previous Gestational Diabetes Completed Merck Sharp & Dohme Corp. Phase 2 2011-05-01 The goal of the present research is to compare the effects of treatment with metformin and sitagliptin, alone or in association, in women with previous gestational diabetes to evaluate the impact of the two drugs on beta-cell function. The study results may contribute to give a rational approach for future investigations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Janumet Xr

Condition Name

Condition Name for Janumet Xr
Intervention Trials
Type 2 Diabetes Mellitus 6
Diabetes Mellitus, Type 2 2
Polycystic Ovary Syndrome 2
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Janumet Xr
Intervention Trials
Diabetes Mellitus, Type 2 10
Diabetes Mellitus 10
Polycystic Ovary Syndrome 2
Glucose Intolerance 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Janumet Xr

Trials by Country

Trials by Country for Janumet Xr
Location Trials
United States 9
Canada 5
United Kingdom 2
Israel 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Janumet Xr
Location Trials
Louisiana 1
Pennsylvania 1
Ohio 1
Michigan 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Janumet Xr

Clinical Trial Phase

Clinical Trial Phase for Janumet Xr
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Janumet Xr
Clinical Trial Phase Trials
Completed 13
Recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Janumet Xr

Sponsor Name

Sponsor Name for Janumet Xr
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Ohio University 1
Temple University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Janumet Xr
Sponsor Trials
Other 13
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.